SB328437干预小鼠变应性鼻炎模型的实验研究

CC chemokine receptor 3 antagonist SB328437 in treatment of mouse model of allergic rhinitis

目的探讨趋化因子受体3(CCR3)拮抗剂SB328437在小鼠变应性鼻炎模型中的防治作用。方法将30只6～8周BALB/c小鼠随机分为变应性鼻炎组(A组)、SB328437治疗组(B组)和正常对照组(C组),每组10只。以卵清白蛋白(OVA)致敏建立变应性鼻炎模型,B组每次激发前0.5h以SB328437 0.8 mL腹壁皮下注射,10μL滴鼻。比较各组小鼠变应性鼻炎症状评分、鼻黏膜嗜酸性粒细胞(EOS)计数、血清IgE含量以及鼻黏膜CCR3荧光强度。结果A、B、C组的症状评分分别为(7.6±1.9)、(0.7±0.6)和(0.5±0.3)分,A组与B、C组的差异均有统计学意义(P值均<0.01),B组与C组的差异无统计学意义(P>0.05)。A、B、C组的EOS计数分别为7.8±1.8、1.6±0.9和0.5±0.3,A组与B、C组的差异均有统计学意义(P值均<0.01),B组与C组的差异无统计学意义(P>0.05)。A、B、C组血清总IgE分别为(120.59±7.92)、(71.77±6.54)和(18.68±4.76)ng/mL,3组间的差异有统计学意义(P<0.01)。B组鼻黏膜CCR3荧光强度低于A组。结论SB328437可抑制小鼠变应性鼻炎,有可能成为变应性鼻炎免疫治疗的一种新方法。

Objective To study the preventive effect of CC chemokine receptor 3 （CCR3） antagonist SB328437 on mouse model of allergic rhinitis. Methods Thirty BALB/C mice were evenly randomized into allergic rhinitis group（group A）, SB328437 treatment group（group B） and normal control group（group C）, Ovalbumin sensitization was used to create allergic rhinitis model in mice, Mice in group B were subcutaneously injected with 0.8 mL SB328437 and were given nasal dropping of 10 μL, SB328437 half an hour before challenge, The symptom score, count of eosinophils, total serum IgE, and the fluorescent intensity of CCR3 in nasal mucosa were compared between the 3 groups, Results The symptom scores in group A（7. 6 ± 1. 9） were significantly higher than those in group B（0. 7 ± 0. 6） and C（0.5 ± 0.3） （both P 〈 0. 01 ） ; no significant difference was observed between the latter 2 groups, The counts of eosinophils in group A（7. 8 ± 1. 8） was also significantly higher than those of group B （1.6±0.9） and C（0. 5±0. 3） （bothP 〈 0.01）, no significant difference was observed between the latter 2 groups, The serum IgE levels in the 3 groups were（120. 59 ±7. 92）, （71. 77 ± 6.54） and（18. 68 ± 4. 76）ng/mL, respectively; there was significant difference between the 3 groups, The fluorescent intensities in group B was lower than that in group A, Conclusion SB328437 may be used as a new immunotherapy agent against allergic rhinitis in mice.